JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SEATTLE, May 30, 2017 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it will webcast the company’s presentation at the 2017 Jefferies Healthcare Conference in New York City, on Wednesday, June 7, 2017.
The webcast is scheduled to begin at 1:30pm ET and will feature a company overview by Brad Gray, president and chief executive officer of NanoString. Interested parties can access the live webcast with accompanying slides from the investor section of the company’s website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentation and archived for 90 days.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,600 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
NanoString, NanoString Technologies, the NanoString logo, 3D Biology, nCounter and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Contact: Doug Farrell Vice President, Investor Relations & Corporate Communications [email protected] Phone: 206-602-1768
